Clinical

Dataset Information

0

Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.


ABSTRACT: Interventions: 1 cycle is 28days. TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 8-12 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. Primary outcome(s): 4 month progression free survival by central assessment( 4M PFS) Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2628236 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2632430 | ecrin-mdr-crc
| 2646936 | ecrin-mdr-crc
| 2641267 | ecrin-mdr-crc
| 2634299 | ecrin-mdr-crc
| 2615622 | ecrin-mdr-crc
| 2609743 | ecrin-mdr-crc
2012-03-25 | GSE35422 | GEO
2010-11-10 | E-GEOD-20878 | biostudies-arrayexpress
2020-05-02 | GSE149723 | GEO
| S-EPMC7677253 | biostudies-literature